Opportunity Information: Apply for RFA CA 27 019

The National Institutes of Health, through the National Cancer Institute (NCI), is offering a cooperative agreement opportunity under the Informatics Technology for Cancer Research (ITCR) Program to support early-stage development of informatics technologies that can strengthen cancer research and cancer data management. The funding opportunity is titled "Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)" (RFA-CA-27-019). It is aimed at projects that build new software, platforms, computational methods, or data resources, or that substantially adapt existing tools for new cancer-related uses, with the goal of improving how cancer data and knowledge are collected, organized, analyzed, and shared across the full cancer research continuum.

A key point is what "early-stage development" means in this program. This NOFO is meant for work ranging from prototyping through initial dissemination, which generally includes building a functional tool (or major new capability), testing it in realistic settings, and making it available in an initial form to intended users. It is not just about generating ideas or publishing algorithms; the emphasis is on creating enabling technology that can be used by cancer researchers and that addresses a clear, recognized need in the field.

The scope is intentionally broad and includes informatics technology that supports many areas of cancer research and management, such as basic cancer biology, cancer diagnosis and treatment, early detection, risk assessment and prevention, cancer epidemiology, and cancer control. The opportunity encourages user-friendly and impactful tools that can serve discovery research, population-based studies, and clinical or translational research. In practice, this could include technologies for data acquisition and integration, management of complex datasets, advanced analytics and modeling, knowledge representation, data sharing and interoperability, workflow tools, or other informatics approaches that make cancer research more efficient, reproducible, and scalable.

To be competitive, applicants need to do more than propose a technically interesting tool. The NOFO stresses that proposals must clearly explain why the technology is needed, what gap it fills, and how it will benefit cancer research beyond a single lab or a narrow use case. Projects are expected to demonstrate novelty in informatics capabilities for the targeted domain and to show strong potential to advance one or more "driving" cancer research projects as well as the broader research community. Another major requirement is a concrete plan to engage end users throughout development, including processes to solicit feedback from the driving projects and other users so that the technology evolves based on real-world needs rather than developer assumptions.

The program also places weight on execution planning. Applications must include a realistic development timeline and clear milestones, reflecting that this is a cooperative agreement (U01), where NIH/NCI typically has substantial scientific involvement during the project period. While clinical trials are optional under this announcement, the mechanism allows projects that may include clinical trial-related elements if appropriate, but they are not required.

In terms of basic logistics, this is a discretionary funding opportunity using a cooperative agreement funding instrument (U01) within the health activity category, associated with CFDA numbers 93.393, 93.394, 93.395, 93.396, and 93.399. The opportunity lists an award ceiling of $300,000 and anticipates making about 5 awards. The opportunity was created on 2026-05-21, and the listed original closing date is 2027-10-19.

Eligibility is broad and includes many types of U.S. organizations and governments, such as state, county, and city governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other eligible tribal organizations; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses. Importantly, the NOFO explicitly allows international participation: non-U.S. entities (foreign organizations) may apply, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined in the NIH Grants Policy Statement.

Overall, this NOFO is best understood as support for practical, research-driven cancer informatics engineering at an early but tangible stage: building or significantly adapting tools that solve real problems in cancer research data and knowledge handling, validating them with engaged users, and moving them toward initial adoption and dissemination with clear milestones and a credible development plan.

  • The National Institutes of Health in the health sector is offering a public funding opportunity titled "Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)" and is now available to receive applicants.
  • Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.394, 93.395, 93.396, 93.399.
  • This funding opportunity was created on 2026-05-21.
  • Applicants must submit their applications by 2027-10-19.
  • Each selected applicant is eligible to receive up to $300,000.00 in funding.
  • The number of recipients for this funding is limited to 5 candidate(s).
  • Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
Apply for RFA CA 27 019

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:

FAQs: Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) - RFA-CA-27-019

What is this funding opportunity?

This is a National Institutes of Health (NIH) funding opportunity offered through the National Cancer Institute (NCI) under the Informatics Technology for Cancer Research (ITCR) Program. It uses a cooperative agreement mechanism (U01) to support early-stage development of informatics technologies that strengthen cancer research and cancer data management. The official title is "Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)" (RFA-CA-27-019).

What is the overall goal of the program?

The goal is to improve how cancer data and knowledge are collected, organized, analyzed, and shared across the full cancer research continuum by supporting development (or substantial adaptation) of practical, user-oriented informatics tools and resources that address clear needs in the cancer research community.

What kinds of projects does this NOFO support?

The NOFO supports projects that build new software, platforms, computational methods, or data resources, or that substantially adapt existing tools for new cancer-related uses. The emphasis is on enabling technology that can be used by cancer researchers and that improves cancer data/knowledge handling in real-world settings.

What does "early-stage development" mean in this opportunity?

"Early-stage development" in this program covers work from prototyping through initial dissemination. In general, this includes building a functional tool (or a major new capability), testing it in realistic settings, and making it available in an initial form to intended users. It is not limited to conceptual ideas or publications; the focus is on creating something usable.

Is this opportunity focused on research papers or on building technology?

The emphasis is on building enabling technology rather than only generating ideas or publishing algorithms. Competitive proposals are expected to produce a functional tool or major new capability and to validate it with users in realistic contexts.

Which areas of cancer research and management are in scope?

The scope is intentionally broad and can include informatics technology supporting basic cancer biology, cancer diagnosis and treatment, early detection, risk assessment and prevention, cancer epidemiology, and cancer control. The opportunity is meant to span the full cancer research continuum.

What types of informatics technologies are encouraged?

Examples of encouraged technology areas include tools for data acquisition and integration, management of complex datasets, advanced analytics and modeling, knowledge representation, data sharing and interoperability, workflow tools, and other informatics approaches that improve efficiency, reproducibility, and scalability of cancer research.

Does the NOFO require novelty, and if so, what kind?

Projects are expected to demonstrate novelty in informatics capabilities for the targeted domain. Novelty here is framed around meaningful new capabilities or substantial adaptations that address a recognized need and provide value beyond a narrow setting.

What makes an application competitive according to the description provided?

Competitive proposals go beyond being technically interesting. They clearly explain why the technology is needed, what gap it fills, and how it benefits cancer research beyond a single lab or narrow use case. They also show strong potential to advance one or more driving cancer research projects and provide broader value to the research community.

What are "driving" cancer research projects in this context?

The NOFO emphasizes that the technology should have strong potential to advance one or more driving cancer research projects, meaning real cancer research efforts that can help ground requirements, guide development priorities, and serve as realistic settings for testing and feedback.

Is end-user engagement required?

Yes. A major requirement is a concrete plan to engage end users throughout development, including processes to solicit feedback from driving projects and other users. The expectation is that the technology evolves based on real-world needs rather than developer assumptions.

What stage of dissemination is expected?

The NOFO targets work through initial dissemination. That typically means making the tool available in an initial form to intended users, after it has been built and tested in realistic settings. The description emphasizes practical availability and initial adoption rather than long-term, fully mature deployment.

What funding mechanism is used, and what does it imply?

This opportunity uses a cooperative agreement (U01). As a cooperative agreement, NIH/NCI typically has substantial scientific involvement during the project period, and applications are expected to present a realistic development plan with clear milestones.

Are clinical trials required?

No. Clinical trials are optional under this announcement. The mechanism allows projects that may include clinical trial-related elements if appropriate, but clinical trials are not required.

What planning and management elements are emphasized?

The program places weight on execution planning. Applications are expected to include a realistic development timeline and clear milestones, aligned with the early-stage development focus and the cooperative agreement nature of the award.

What is the award ceiling and how many awards are anticipated?

The opportunity lists an award ceiling of $300,000 and anticipates making about 5 awards.

When was this opportunity created and when does it close?

The opportunity was created on 2026-05-21. The listed original closing date is 2027-10-19.

Which agency and program are offering this opportunity?

The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering this opportunity under the Informatics Technology for Cancer Research (ITCR) Program.

What is the activity category and what CFDA numbers are associated with it?

This is a discretionary funding opportunity in the health activity category. It is associated with CFDA numbers 93.393, 93.394, 93.395, 93.396, and 93.399.

Who is eligible to apply?

Eligibility is broad and includes many types of U.S. organizations and governments: state, county, and city governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other eligible tribal organizations; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses.

Are international (non-U.S.) organizations allowed to apply?

Yes. The NOFO explicitly allows international participation: non-U.S. entities (foreign organizations) may apply, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined in the NIH Grants Policy Statement.

Is this opportunity limited to academic institutions?

No. Based on the listed eligibility, the opportunity is open to a wide range of applicants, including academic institutions, nonprofits, for-profit organizations, small businesses, and various government and tribal entities, including eligible international organizations and components.

Does the NOFO favor tools that are usable beyond a single lab?

Yes. The description stresses that proposals should explain how the technology will benefit cancer research beyond a single lab or narrow use case and should be useful to the broader research community.

What is the best high-level way to think about this NOFO?

It is support for practical, research-driven cancer informatics engineering at an early but tangible stage: building or significantly adapting tools that solve real problems in cancer research data and knowledge handling, validating them with engaged users, and moving them toward initial adoption and dissemination with clear milestones and a credible development plan.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: State Pilot Program for Treatment for Pregnant and Postpartum Women

Previous opportunity: Innovation and Tech Lab

Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA CA 27 019

 

Applicants also applied for:

Applicants who have applied for this opportunity (RFA CA 27 019) also looked into and applied for these:

Funding Opportunity
Novel Experiential Technologies Assisting Individual Learning (NExT AI) Hubs (P20 Clinical Trial Optional) Apply for RFA HD 27 006

Funding Number: RFA HD 27 006
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 CT Not Allowed) Apply for RFA HD 27 007

Funding Number: RFA HD 27 007
Agency: National Institutes of Health
Category: Health
Funding Amount: $200,000
NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed) Apply for PAR 27 058

Funding Number: PAR 27 058
Agency: National Institutes of Health
Category: Health
Funding Amount: $500,000
Causal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions (U01 Clinical Trial Not Allowed) Apply for PAR 27 057

Funding Number: PAR 27 057
Agency: National Institutes of Health
Category: Health
Funding Amount: $500,000
Influenza Modeling and Forecasting Apply for CDC RFA IP 26 0102

Funding Number: CDC RFA IP 26 0102
Agency: Centers for Disease Control - NCIRD
Category: Health
Funding Amount: Case Dependent
Research Grants for Preventing Interpersonal Violence and Suicide Among Youth and Young Adults (R01) Apply for RFA CE 26 020

Funding Number: RFA CE 26 020
Agency: Centers for Disease Control and Prevention - ERA
Category: Health
Funding Amount: $400,000
Eliminating Parasitic and Neglected Tropical Disease Threats to the United States - Program Support and Research to Reduce Threats to Americans at Home and Abroad Apply for RFA CK 26 104

Funding Number: RFA CK 26 104
Agency: Centers for Disease Control and Prevention - ERA
Category: Health
Funding Amount: $1,000,000
Addressing Dementia in Tribal and Urban Indian Communities: CAReS Program Apply for HHS 2026 IHS ALZ 0001

Funding Number: HHS 2026 IHS ALZ 0001
Agency: Indian Health Service
Category: Health
Funding Amount: $750,000
Tribal Self-Governance Planning Cooperative Agreement Program Apply for HHS 2026 IHS TSGP 0001

Funding Number: HHS 2026 IHS TSGP 0001
Agency: Indian Health Service
Category: Health
Funding Amount: $180,000
A Tribal Self-Governance Negotiation Cooperative Agreement Program Apply for HHS 2026 IHS TSGN 0001

Funding Number: HHS 2026 IHS TSGN 0001
Agency: Indian Health Service
Category: Health
Funding Amount: $84,000
Tribal Management Grant (TMG) Program Apply for HHS 2026 IHS TMD 0001

Funding Number: HHS 2026 IHS TMD 0001
Agency: Indian Health Service
Category: Health
Funding Amount: $300,000
Strengthening public health efforts to protect and improve health in the Democratic Republic of the Congo (DRC) Apply for CDC RFA JG 26 0044

Funding Number: CDC RFA JG 26 0044
Agency: Centers for Disease Control-GHC
Category: Health
Funding Amount: Case Dependent
Sustaining Global Health Security to protect and improve public health in Kenya Apply for CDC RFA JG 26 0055

Funding Number: CDC RFA JG 26 0055
Agency: Centers for Disease Control-GHC
Category: Health
Funding Amount: Case Dependent
Enhancing global laboratory systems to safely manage biological risks, deploy diagnostics, and sequence pathogens to improve capacities for global health threat response and detection Apply for CDC RFA JG 26 0058

Funding Number: CDC RFA JG 26 0058
Agency: Centers for Disease Control-GHC
Category: Health
Funding Amount: Case Dependent
Strengthening Global Health Security by improving public health capacity to detect, notify, and respond to disease outbreaks globally Apply for CDC RFA JG 26 0056

Funding Number: CDC RFA JG 26 0056
Agency: Centers for Disease Control-GHC
Category: Health
Funding Amount: Case Dependent
Strengthening global health security through local partnerships in Uganda Apply for CDC RFA JG 26 0054

Funding Number: CDC RFA JG 26 0054
Agency: Centers for Disease Control-GHC
Category: Health
Funding Amount: Case Dependent
Limited Competition: Instrumentation Grant Program for Resource-Limited Institutions (S10 - Clinical Trial Not Allowed) Apply for PAR 27 067

Funding Number: PAR 27 067
Agency: National Institutes of Health
Category: Health
Funding Amount: $250,000
Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (U54 Clinical Trial Not Allowed) Apply for RFA DA 27 015

Funding Number: RFA DA 27 015
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required) Apply for RFA DK 27 121

Funding Number: RFA DK 27 121
Agency: National Institutes of Health
Category: Health
Funding Amount: $1,000,000
Silvio O. Conte Digestive Diseases Research Core Centers (P30-Clinical Trial Optional) Apply for RFA DK 27 119

Funding Number: RFA DK 27 119
Agency: National Institutes of Health
Category: Health
Funding Amount: $750,000

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

Inside Our Applicants Portal

  • Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
  • Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
  • Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Access Applicants Portal

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Learn More

 

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 27 019", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.

 

Ask a Question: